Dossier overview
4
research areas
3
references
3
handling notes
01
Mechanism of action
Semaglutide activates the GLP-1 , augmenting glucose-dependent insulin secretion, suppressing inappropriate glucagon release, delaying gastric emptying, and reducing appetite signalling via central GLP-1 receptor expression. The C18 fatty diacid side chain provides high albumin affinity and prolonged plasma .
02
Research applications
- Type 2 diabetes glycaemic-control clinical research
- Obesity and weight-management clinical research
- Cardiovascular outcome research (SELECT trial)
- GLP-1 pharmacology and incretin physiology
Evidence at a glance
What's behind this profile
3 citations · 2021–2022
- Human
- 3
Studies in human volunteers or patients (incl. early-phase trials).
Publication years
- 21
- 22
Counts are derived from the cited studies below. A study covering both in vivo and in vitro work is counted by its primary model. Sample size is reported in 3 of 3 citations. Findings remain model-specific and are not extrapolated to therapeutic use.
03
Study references
Each profile cites a minimum of two peer-reviewed sources, with model type and reported sample size where the source provides it. Findings are model-specific and must not be extrapolated to therapeutic use.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
2021
Wilding JPH et al. · New England Journal of Medicine
- Model
- Phase 3 double-blind RCT in adults with overweight/obesity without type 2 diabetes
- Sample
- n=1961
Once-weekly semaglutide 2.4 mg was associated with mean body weight reduction of 14.9% versus 2.4% with placebo over 68 weeks.
Effect of Subcutaneous Semaglutide vs Placebo as Adjunct to Intensive Behavioral Therapy on Body Weight (STEP 3)
2021
Wadden TA et al. · JAMA
- Model
- Phase 3a double-blind RCT in adults with overweight/obesity (without diabetes) plus intensive behavioural therapy
- Sample
- n=611
Semaglutide 2.4 mg with behavioural therapy was associated with mean body weight reduction of 16.0% versus 5.7% with placebo over 68 weeks.
Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
2022
Garvey WT et al. · Nature Medicine
- Model
- Phase 3 double-blind RCT in adults with overweight/obesity without type 2 diabetes
- Sample
- n=304
Semaglutide 2.4 mg was associated with sustained mean body weight reduction of 15.2% versus 2.6% with placebo over 104 weeks.
Evidence caveats
- FDA approval covers specific indications. Clinical use is a medical decision and is not endorsed here.
- Long-term safety surveillance is ongoing across multiple post-marketing studies. This profile summarises the primary STEP-programme registrational evidence.
04
Storage and handling
Approved product follows manufacturer cold-chain instructions. Research-grade material must be stored under controlled laboratory conditions per protocol.
- Approved product follows the manufacturer label and pharmacy cold-chain.
- Research-grade material requires controlled laboratory storage and full batch documentation.
- Clinical decisions involving semaglutide require a qualified healthcare professional.